MedTrace Logo

RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial

NCT06658977 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-08

No results posted yet for this study

Summary

Triumeq is an approved medicine for HIV. The effectiveness of Triumeq in Amyotrophic Lateral Sclerosis (ALS) is being investigated in the Lighthouse II trial. This study aims to assess whether Triumeq is safe and effective at delaying ALS disease progression when given long term. It is available for participants who have completed the Lighthouse II study. The main measurements are safety, tolerability and survival.

The study will go for approximately 2 years.

Conditions

Interventions

DRUG

Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)

One Triumeq tablet per day

Sponsors & Collaborators

  • Macquarie University, Australia

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-15
Primary Completion
2025-06-03
Completion
2025-06-03

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06658977 on ClinicalTrials.gov